$OMER

Borges David J. sold $85K of OMER

Borges David J. (VP, Finance & CAO) sold 5,000 shares of OMEROS CORP (OMER) at $16.95 on 2026-08-13 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Borges David J.
Published Aug 17, 2026, 11:42 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 17, 2026, 11:43 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$OMER
Neutral
high confidence
Mentioned
$OMER
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$OMERNeutralLow
01

Why it matters

The disclosed event is an open-market sale by an officer under a pre-arranged 10b5-1 plan, which typically has limited informational content about near-term fundamentals.

02

Market read

Traders may monitor insider activity, but this specific disclosure is unlikely to drive a fundamental repricing without accompanying company news.

03

What to watch

The article provides no context on total insider holdings beyond the post-transaction 0 shares, and it does not indicate whether other insiders sold or whether there were concurrent company-specific catalysts.

Relevance 2/10Novelty 2/10Timing: Form 4 filed 2026-08-17 for a sale dated 2026-08-13

Background

The article is an SEC Form 4 insider transaction disclosure for OMEROS CORP.

Company-level read

Ticker impact

$OMERNeutralHigh confidence
Context

OMEROS CORP disclosed an insider open-market sale by VP, Finance & CAO Borges David J. of 5,000 shares at $16.95 on 2026-08-13.

Expected impact

Likely limited near-term impact; any effect is typically sentiment-only and outweighed by the pre-arranged nature.

Evidence & confidence

The filing specifies a pre-arranged Rule 10b5-1 plan and an open-market sale, which generally reduces interpretive signal versus discretionary selling.

Market effects

No sector-level implications; this is company-specific insider transaction disclosure.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, some traders may still view insider selling as a mild negative signal, especially if it coincides with other bearish developments not mentioned here.

Key entities

  • OMEROS CORP

    Company subject of the Form 4 insider transaction disclosure.

  • Borges David J.

    VP, Finance & CAO who sold 5,000 shares under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$AZNMedAI 8/10

CHMP October decisions: AstraZeneca pulls prostate cancer filing; Orphelia gets a second chance; Ascendis nears EU launch

AstraZeneca withdrew its EU application for Truqap in prostate cancer. Orphelia Pharma gained CHMP backing for Kizfizo in glioblastoma. Ascendis Pharma neared EU approval for Yuviwel in achondroplasia. Sobi expanded Tryngolza's use to severe hypertriglyceridemia. Pfizer withdrew Ibrance's EU expansion. Revolution Medicines got CHMP backing for Rasonque in pancreatic cancer. Omeros failed to overturn Yartemlea's EU rejection. Lilly advanced Foundayo for obesity and diabetes in Europe.

$OMERHighAI 8/10

Why is Omeros stock sliding today?

Omeros (OMER) stock fell 5.4% in pre-market trading after the European Medicines Agency's committee issued a second negative opinion on its Yartemlea drug application. The company will end its European compassionate-use program and abandon plans to license EU commercialization rights. Insiders sold $3M in shares over the past year. The stock traded at $17.77, down from $18.79. The U.S. launch of Yartemlea remains on track, with next earnings expected in mid-November.